Built for the week six plateau, the cost and coverage gap, and the long arc of adherence after the first injection.
Discontinuation rarely comes from the molecule. It comes from the plateau no one warned them about, the coverage letter that never arrived, and the transition no one mapped when compounded supply ended. Four numbers describe the gap.
A decision engine built for the week six-to-twelve window. When the scale stops moving, the companion knows what to suggest next.
Injection timing, biometrics, symptoms, and nutrition in one place. Connects the dose day to the symptom day — structured for clinical use.
Peer support anonymized by week of therapy, not by name. Protocol-specific nuance without social stigma or identity risk.
Access navigation for cost and coverage. Medication transition guidance for users moving off compounded therapy. Scheduled wellbeing check-ins at weeks four, eight, and twelve.
Two-thirds of weight lost on therapy is regained within one year of discontinuation (STEP-4). The companion stays with the user across the full arc — from the first injection, through the plateau window, and into maintenance.
Built for users on semaglutide, tirzepatide, and the next wave of incretins. One email when access opens. No marketing, no list swaps.
CDISC-compliant data architecture, Expert Determination de-identification, tiered partner access.
Contact partnerships →Structured intake, decision support under the revised January 2026 FDA CDS framework.
For clinicians →Deck, supporting RWE analysis, and market sizing model available under mutual NDA.
Request the deck →